Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2023)
Orchestra BioMed Holdings' (OBIO) quarterly Gains from Investment Securities came in at $294000.0 in Q1 2023, up 102.76% year-on-year from $145000.0 in Q1 2022, and up 30.09% on a QoQ basis from $226000.0 in Q4 2022.
Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2023) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 2 years of Gains from Investment Securities data on file, last reported at $294000.0 in Q1 2023.
- On a quarterly basis, Gains from Investment Securities rose 102.76% year-over-year to $294000.0 in Q1 2023; TTM through Dec 2023 was $294000.0, a 78.22% decrease from a year earlier, with the FY2023 full-year figure at $294000.0, down 78.22% from the prior year.
- Gains from Investment Securities for Q1 2023 stood at $294000.0, up from $226000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for OBIO reached as high as $1.0 million in Q2 2022 and fell as low as -$36000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Orchestra BioMed Holdings | 240.54 Mn | 146.14 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 294,000.00 |
| Mar 31, 2023 | 294,000.00 |
| Dec 31, 2022 | 226,000.00 |
| Dec 31, 2022 | 226,000.00 |
| Sep 30, 2022 | -36,000.00 |
| Sep 30, 2022 | -36,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 145,000.00 |
| Mar 31, 2022 | 145,000.00 |